Shots:

• The agreement leverages Imbio's technical- regulatory & commercial expertise to build medical imaging AI technology for use in research- clinical trials & clinical practice
• The focus of the agreement is to develop quantitative imaging diagnostics for lung diseases and to bring unique solutions for pulmonary imaging. The collaboration integrates Imbio's expertise in imaging biomarkers with Genentech's pulmonary disease expertise for enhancing drug development and delivering more personalized healthcare
• Imbio will continue to develop & market its portfolio of quantitative imaging algorithms for lung & cardiothoracic diseases apart from the collaboration
  
   ­ Ref: PR Newswire | Image: UT Health